文献速递药物相互作用

基于生理药代动力学模型评估难溶性药物口服吸收中溶解度作用

Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic Modeling.
PubMed 文献 · Clin Pharmacol Ther · 2019-11-21

该文基于10种难溶性酪氨酸激酶抑制剂,利用生理药代动力学分析与早期临床PK数据,识别吸收真正受溶解度限制的药物,并支持采用整体证据方法指导食物及酸抑制剂相互作用研究决策。

要点

  • 体外溶解度可能低估体内真实溶解度,导致药物误分类。
  • 结合PBPK与早期临床PK可识别溶解度限制吸收的药物。
  • 整体证据方法可指导食物及酸抑制剂相互作用研究设计。

核心结论

  • 基于10种难溶性酪氨酸激酶抑制剂,PBPK分析结合早期临床PK数据可识别吸收真正受溶解度限制的药物。

研究设计与样本

  • 基于10种难溶性酪氨酸激酶抑制剂的生理药代动力学分析,结合早期临床PK数据。

主要发现

  • 体外药物溶解度可能低估体内真实溶解度并导致药物误分类。
  • 吸收真正受溶解度限制的药物预期表现出食物效应。

临床怎么用

  • 使用早期临床数据与PBPK分析整体证据指导食物及酸抑制剂相互作用研究决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Poor aqueous solubility and dissolution of drug candidates drive key decisions on lead series optimization during drug discovery, on formulation optimization, and clinical studies planning during drug development. The interpretation of the in vivo relevance of early pharmaceutical profiling is often confounded by the multiple factors affecting oral systemic exposure. There is growing evidence that in vitro drug solubility may underestimate the true in vivo solubility and lead to drug misclassification. Based on 10 poorly water-soluble tyrosine kinase inhibitors, this paper demonstrates the use of physiologically-based pharmacokinetic (PK) analysis in combination with early clinical PK data to identify drugs whose absorption is truly limited by solubility in vivo and, therefore, expected to exhibit food effect. Our study supports a totality of evidence approach using early clinical data to guide decisions on conducting drug interaction studies with food and acid-reducing agents.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fink C, Sun D, Wagner K, et al. Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic Modeling. Clin Pharmacol Ther. 2019. PMID: 31608434. doi:10.1002/cpt.1672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。